GSK’s new asthma drug Relvar Ellipta has shown itself to be superior ... FF/VI or to continue on their existing asthma maintenance therapy (usual care). It had minimal exclusion criteria ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from ... revealed that its new ‘closed triple therapy’ has shown very strong results in ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...